PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis (clinicaltrials.gov) - May 29, 2026 - P4 | N=150 | Recruiting | Sponsor: Aurinia Pharmaceuticals Inc.
New P4 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|